Immuno Oncology Diagnosis Market Report 2026
Global Outlook – By Product Type ( Assays, Kits, Reagents, Instruments, Software), By Technology ( Polymerase Chain Reaction, Next Generation Sequencing, Immunohistochemistry, Flow Cytometry, Other Technologies), By Application ( Cancer Diagnosis, Research, Drug Development, Other Applications), By End User ( Hospitals, Diagnostic Laboratories, Academic And Research Institutes, Pharmaceutical And Biotechnology Companies) – Market Size, Trends, Strategies, and Forecast to 2030
Immuno Oncology Diagnosis Market Report 2026 Market Overview
• Immuno Oncology Diagnosis Market Report 2026 market size has reached to $13.8 billion in 2025 • Expected to grow to $22.16 billion in 2030 at a compound annual growth rate (CAGR) of 10% • Growth Driver: Surge In Global Cancer Cases Fueling The Growth Of The Market Due To Rising Demand For Precision Oncology And Biomarker-Based Diagnostic Testing • Market Trend: Integration Of Artificial Intelligence And Molecular Profiling Transforming Personalized Cancer Care • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Immuno Oncology Diagnosis Market?
Immuno-oncology diagnosis refers to detecting and analyzing cancer-related biomarkers and immune responses to better understand the relationship between tumors and the immune system. It helps identify cancer characteristics, supports accurate diagnosis, and guides treatment decisions. Immuno-oncology diagnoses enable patient stratification, optimize therapy selection, and monitor treatment effectiveness, improving overall cancer care outcomes. The main product types of immuno oncology diagnosis include assays, kits, reagents, instruments, and software. Assays refer to diagnostic tests designed to detect, measure, and analyze biological markers associated with immune responses and cancer conditions. These products use technologies such as polymerase chain reaction, next generation sequencing, immunohistochemistry, flow cytometry, and other technologies. They find application in cancer diagnosis, research, drug development, and others, serving end users including hospitals, diagnostic laboratories, academic and research institutes, and pharmaceutical and biotechnology companies.
What Is The Immuno Oncology Diagnosis Market Size and Share 2026?
The immuno oncology diagnosis market size has grown strongly in recent years. It will grow from $13.8 billion in 2025 to $15.15 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to rising global cancer incidence rates, increasing adoption of targeted cancer therapies, expansion of hospital based diagnostic laboratories, growing use of immunohistochemistry techniques in oncology, improvements in biomarker discovery technologies.What Is The Immuno Oncology Diagnosis Market Growth Forecast?
The immuno oncology diagnosis market size is expected to see strong growth in the next few years. It will grow to $22.16 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increasing demand for personalized cancer immunotherapy, expansion of liquid biopsy and non invasive diagnostics, rising adoption of ai driven diagnostic platforms, growth in precision medicine and companion diagnostics, increasing investment in oncology research and clinical trials. Major trends in the forecast period include liquid biopsy based immuno-oncology diagnostic assays for early cancer detection and monitoring, multiplex immune profiling platforms for tumor microenvironment characterization, companion diagnostic kits for personalized cancer immunotherapy selection, high sensitivity flow cytometry based immune cell analysis for cancer stratification, ai enabled digital pathology software for immuno-oncology biomarker interpretation.
Global Immuno Oncology Diagnosis Market Segmentation
1) By Product Type: Assays, Kits, Reagents, Instruments, Software 2) By Technology: Polymerase Chain Reaction, Next Generation Sequencing, Immunohistochemistry, Flow Cytometry, Other Technologies 3) By Application: Cancer Diagnosis, Research, Drug Development, Other Applications 4) By End User: Hospitals, Diagnostic Laboratories, Academic And Research Institutes, Pharmaceutical And Biotechnology Companies Subsegments: 1) By Assays: Protein Biomarker Assays, Genomic Biomarker Assays, Multiplex Immunoassays, Companion Diagnostic Assays, Tumor Mutation Detection Assays, Immune Profiling Assays, Circulating Tumor Cell Assays, Liquid Biopsy Assays, Cell Based Functional Assays, Spatial Biology Assays 2) By Kits: Sample Preparation Kits, Nucleic Acid Extraction Kits, Biomarker Detection Kits, Immunohistochemistry Kits, Flow Cytometry Kits, Polymerase Chain Reaction Kits, Sequencing Library Preparation Kits, Tumor Profiling Kits, Companion Diagnostic Kits, Cell Isolation Kits 3) By Reagents: Antibodies Reagents, Staining Reagents, Detection Reagents, Buffer Reagents, Fluorescent Labeling Reagents, Enzyme Substrate Reagents, Cell Culture Reagents, Molecular Probe Reagents, Contrast Enhancement Reagents, Blocking Reagents 4) By Instruments: Flow Cytometry Instruments, Digital Pathology Instruments, Sequencing Instruments, Polymerase Chain Reaction Instruments, Microscopy Instruments, Immunoassay Analyzers, Slide Scanning Instruments, Cell Imaging Instruments, Automated Sample Preparation Instruments, Biomarker Analysis Instruments 5) By Software: Bioinformatics Software, Clinical Decision Support Software, Image Analysis Software, Data Management Software, Sequencing Analysis Software, Laboratory Information Management Software, Digital Pathology Software, Biomarker Interpretation Software, Artificial Intelligence Diagnostic Software, Cloud Based Analytics SoftwareWhat Is The Driver Of The Immuno Oncology Diagnosis Market?
The increasing prevalence of cancer worldwide is expected to propel the growth of the immuno-oncology diagnosis market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells that can invade surrounding tissues and spread to other parts of the body, disrupting normal bodily functions. Cancer incidence is increasing due to the expanding aging population, as advancing age leads to the accumulation of genetic mutations and cellular damage, significantly elevating the risk of tumor development. Immuno-oncology diagnosis supports cancer treatment by enabling biomarker identification, immune profiling, and precision oncology testing required for personalized and targeted cancer therapies, improving treatment effectiveness, patient outcomes, and clinical decision-making. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, by 2050, over 35 million new cancer cases were projected, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer worldwide is driving the growth of the immuno-oncology diagnosis market.Key Players In The Global Immuno Oncology Diagnosis Market
Major companies operating in the immuno oncology diagnosis market report are Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Merck KGaA, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Bio-Techne Corporation, Natera Inc., Caris Life Sciences Inc., Myriad Genetics Inc., NeoGenomics Inc., Guardant Health Inc., Promega Corporation, Takara Bio Inc., Bioneer Corporation, Vazyme Biotech Co. Ltd., Exact Sciences Corporation, Hologic Inc., Becton Dickinson and Company
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Immuno Oncology Diagnosis Market Trends and Insights
Major companies operating in the immuno-oncology diagnosis market are focusing on developing innovative solutions, such as AI-enabled multimodal immune profiling tests, to enhance precision cancer diagnosis, improve treatment response prediction, and support personalized immunotherapy decision-making. AI-enabled multimodal immune profiling tests are advanced diagnostic tools that use artificial intelligence to analyze multiple biological data types, such as genomic, proteomic, and immune biomarkers, to evaluate immune system responses and guide personalized cancer treatment decisions. For instance, in November 2024, Tempus AI, Inc., a US-based artificial intelligence and precision medicine company, launched the Immune Profile Score (IPS) algorithmic test, an AI-enabled multimodal immune profiling test. It is designed to enhance the assessment of immune response patterns and support more informed immuno-oncology treatment decision-making for cancer patients. The IPS test is a multimodal biomarker assay that combines DNA and RNA sequencing insights with clinical and molecular data to generate a predictive immune response score ranging from 0 to 100.What Are Latest Mergers And Acquisitions In The Immuno Oncology Diagnosis Market?
In July 2025, Alden Scientific, a US-based research institute and health technology company, acquired Oncimmune Germany GmbH for an undisclosed amount. Through this acquisition, Alden Scientific aims to strengthen its global leadership in precision medicine by expanding its immune profiling, autoantibody biomarker discovery, and multi-omic analytics capabilities, while gaining access to Oncimmune’s ImmunoINSIGHTS platform and its antigen library covering 9,000+ human and multi-species antigens. Oncimmune Germany GmbH is a Germany-based provider of immuno-oncology diagnoses, particularly under the biomarker discovery, immune profiling, and immunodiagnostic services.
Regional Outlook
North America was the largest region in the immuno oncology diagnosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Immuno Oncology Diagnosis Market?
The immuno-oncology diagnosis market consists of revenues earned by entities by providing services such as biomarker testing, molecular diagnostics, immunohistochemistry, flow cytometry, next-generation sequencing, companion diagnostics, and tumor profiling solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The immuno-oncology diagnosis market also includes sales of biomarker panels, companion diagnostics, molecular profiling tools, and digital pathology systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Immuno Oncology Diagnosis Market Report 2026?
The immuno oncology diagnosis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the immuno oncology diagnosis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Immuno Oncology Diagnosis Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $15.15 billion |
| Revenue Forecast In 2030 | $22.16 billion |
| Growth Rate | CAGR of 10% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Product Type, Technology, Application, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. |
| Key Companies Profiled | Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Merck KGaA, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Bio-Techne Corporation, Natera Inc., Caris Life Sciences Inc., Myriad Genetics Inc., NeoGenomics Inc., Guardant Health Inc., Promega Corporation, Takara Bio Inc., Bioneer Corporation, Vazyme Biotech Co. Ltd., Exact Sciences Corporation, Hologic Inc., Becton Dickinson and Company |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |